Therapeutical uses of eslicarbazepine

Abstract

New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions.

1 .- 25 . (canceled) 
     
     
         26 . A method for treating an intractable epilepsy condition comprising administering to a subject in need thereof a therapeutically effective amount of eslicarbazepine or eslicarbazepine acetate, wherein the subject has previously been treated with a medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins. 
     
     
         27 . The method of  claim 26 , wherein the eslicarbazepine or eslicarbazepine acetate is administered in the absence of a P-glycoprotein inhibitor or a Multiple Resistant Protein inhibitor. 
     
     
         28 . The method of  claim 26 , wherein the intractable state of the condition is due to overexpression of P-glycoprotein and/or Multiple Resistant Proteins. 
     
     
         29 . The method of  claim 26 , wherein the intractable condition is a pharmacoresistant condition. 
     
     
         30 . The method of  claim 26 , wherein the intractable condition is a refractory condition. 
     
     
         31 . The method of  claim 26 , wherein the subject is administered with a therapeutically effective amount of eslicarbazepine acetate. 
     
     
         32 . The method of  claim 26 , wherein the subject is administered with a therapeutically effective amount of eslicarbazepine. 
     
     
         33 . The method of  claim 26 , wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is phenytoin. 
     
     
         34 . The method of  claim 26 , wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is phenobarbital. 
     
     
         35 . The method of  claim 26 , wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is carbamazepine. 
     
     
         36 . The method of  claim 26 , wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is oxcarbazepine. 
     
     
         37 . The method of  claim 26 , wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is felbamate. 
     
     
         38 . The method of  claim 26 , wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is lamotrigine. 
     
     
         39 . The method of  claim 26 , where the subject is pharmacoresistant to the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins. 
     
     
         40 . The method of  claim 26 , where the subject is refractory to the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins. 
     
     
         41 . The method of  claim 26 , wherein the eslicarbazepine or eslicarbazepine acetate is administered as a monotherapy for treating the intractable epilepsy condition. 
     
     
         42 . The method of  claim 26 , wherein the eslicarbazepine or eslicarbazepine acetate is administered as an adjunctive therapy with at least one other anti-epileptic drug for treating the intractable epilepsy condition.